Clinical Trials Logo

ADHD clinical trials

View clinical trials related to ADHD.

Filter by:

NCT ID: NCT06297135 Recruiting - ADHD Clinical Trials

A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This study evaluates the feasibility and preliminary impacts of a new parent support program consisting of a series of educational videos, delivered via a popular texting platform. For this pilot project, the program content is focused on teaching parents strategies to better manage one of the commonly reported challenges children face, a transition to a non-preferred activity. Parents with children demonstrating inattentive, hyperactive and impulsive behavior and experiencing difficulties with daily transition routines are invited to participate in the study.

NCT ID: NCT06284655 Not yet recruiting - ADHD Clinical Trials

The Effect of a Brief Educational Intervention for Adults With ADHD

Start date: March 2024
Phase: N/A
Study type: Interventional

This RCT-study proposes the evaluation of an intensive educational intervention tailored for adults with Attention Deficit Hyperactivity Disorder (ADHD) in community mental health centers (CMHCs). Given the prevalent challenges of prolonged waiting lists and low patient engagement in CMHCs, the research seeks to assess the efficacy of this intervention in enhancing patient engagement, self-efficacy, satisfaction with the information and overall health outcomes. The intervention, developed collaboratively with user representatives, combines a brief group-based educational sessions with standard clinical care. The primary hypotheses posit that this approach will lead to increased patient satisfaction with the treatment, patient self-efficacy, and activation compared to conventional treatment. Additionally, it aims to improve patients' satisfaction with information received. The study will employ a ITT analysis to assess the intervention's effects against usual treatment practices in outpatient settings. The anticipated outcome is a significant improvement in level of patient satisfaction, level of self-efficacy and level of satisfaction with the received information for patients with ADHD, potentially informing clinical practices and optimizing care for adults with ADHD.

NCT ID: NCT06199362 Active, not recruiting - Anemia Clinical Trials

Early Life Anemia and Children's Risk of Neurodevelopmental Disorders: National and Regional Register-based Studies

Start date: August 15, 2023
Phase:
Study type: Observational [Patient Registry]

The overall project aim is to study children's neurodevelopmental outcomes (including diagnoses of autism, ADHD, and intellectual disability) following exposure to maternal anemia during pregnancy or anemia during the first year of life using national and regional Swedish health-data registers, and to assess children's neurodevelopmental outcomes over the range of maternal hemoglobin levels during pregnancy.

NCT ID: NCT06189703 Not yet recruiting - ADHD Clinical Trials

tRNS Treatment for ADHD Symptoms

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.

NCT ID: NCT06169709 Recruiting - ADHD Clinical Trials

An Online Survey for Women With Attention Deficit Hyperactivity Disorder (ADHD)

Start date: February 20, 2024
Phase:
Study type: Observational

The goal of this exploratory study following a cross-sectional online survey in women with ADHD is to 1. describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains; 2. determine which life domains are most affected by ADHD symptoms; 3. calculate the prevalence of reported health conditions within the following domains: circulatory system, endocrine or metabolic system, gastrointestinal system, genitourinary system, musculoskeletal system, nervous system, respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19, sensory sensitivity, menstrual cycle, and sleep; 4. identify topics that women with ADHD would like to see studied in future research.

NCT ID: NCT06155201 Recruiting - Depressive Disorder Clinical Trials

Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The prevalence of mental disorders and developmental behavioral disorders (such as depressive disorders,anxiety disorders, autism spectrum disorders,attention deficit disorder,ect.)among children and adolescents in China is increasing,leading to difficulty in early identification of children and poor diagnosis and treatment effects,which brings significant financial burden to the families and the country.We will carry out a multi-center epidemiological survey on common mental disorders above among children and adolescents in Sichuan-Chongqing region and clarify the prevalence,geographical distribution and demographic characteristics.A total of more than 12,000 children and adolescents under 18 years old with a diagnosis of depression/anxiety disorders/ASD/ADHD based on DSM-5 criteria is included to build a research platform and database,so that we will formulate intelligence diagnosis and treatment standards.This study will establish the "Children and Adolescents Mental and Developmental Disabilities Innovation Alliance" in Sichuan and Chongqing areas and finally build intelligent early warning,diagnosis and intervention systems for disease in hope that technology transformation to be promoted and applied.

NCT ID: NCT06146595 Not yet recruiting - ADHD Clinical Trials

Prevalence of Attention Deficit Hyperactivity Disorder and Its Comorbidities

Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Estimate the prevalence of attention deficit hyperactivity disorder and comorbid psychiatric disorder among primary school students in New Valley governorate.

NCT ID: NCT06142786 Not yet recruiting - ADHD Clinical Trials

Individualized Alpha Neurofeedback for ADHD

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders, characterised by inattention, hyperactivity, and impulsivity. Although pharmacotherapy is considered the first-line treatment for ADHD at all ages (at least for severe cases), non-pharmacological therapies might be equally effective without the risk of drug side effects. Some studies have shown that electroencephalographic (EEG) neurofeedback improves parent-rated ADHD symptoms in children and adolescents. However, whether neurofeedback is an effective treatment for ADHD is still under debate. Several issues may hinder the evaluation of the effectiveness of neurofeedback treatment in previous studies. Firstly, previous neurofeedback studies did not utilize effective neurophysiological markers for ADHD. Theta/Beta ratio, the most common neurofeedback marker for treating ADHD in the past two decades, has recently been suggested to be only weakly correlated to individuals' attention. Secondly, previous studies mostly used the norm of the EEG markers in age/gender matched healthy children as the training target for ADHD children, which largely ignored the individual variations in EEG acquisition. Third, most of the previous studies lack a rigorous study design, for comparing neurofeedback with a 'placebo' condition and evaluating its specific and non-specific effects. In the current studies, we propose to conduct a sham-controlled, triple-blind trial to evaluate the effectiveness of an individual-based neurofeedback treatment for ADHD children and adolescents. The EEG marker for neurofeedback in treating ADHD would be the individualized lower/higher alpha band power, based on the recent methodological advances in EEG spectrum processing (1/f model fit and individualized peak alpha frequency modelling) . The training target will be individualized and defined according to the neurophysiological pattern shown in pre-training resting-state conditions, and thus each participant will be trained to achieve their own optimum state of engagement. Sham neurofeedback will be used as a placebo condition, controlling for the non-specific effect of neurofeedback. The study will be triple-blinded (i.e, participants, individuals who administered treatment or intervention, and those who assessed the outcomes were masked).

NCT ID: NCT06115200 Not yet recruiting - Depression Clinical Trials

Norwegian Adult Mental Health Registry

NAMHR
Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

"The Norwegian Adult Mental Health Registry" (NAMHR) is a medical quality register collecting and systematizing data on patients and their treatment in specialist mental health care for adults in Norway. The main purpose is to create a documentation basis for quality assurance, evaluation, and improvement of assessment and treatment for patients who are offered treatment for mental disorders in the specialist health service. The register uses automatic data capture from various existing data sources. New patients are automatically included, but given the opportunity for reservations from the register without affecting their services and treatment.

NCT ID: NCT06109337 Recruiting - ADHD Clinical Trials

Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder

Start date: December 4, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about The immune cell landscape of peripheral blood mononuclear cells in children with ADHD compared to typically developing controls. The main question it aims to answer are: 1.Testing the differences in immune cell subpopulations, protein expression and signaling pathways and cell subsets between two groups 2. Exploring the correlations between immune function in PBMC and resting-state brain functional networks in children with ADHD. Participants will be taken peripheral blood about 5 ml , cognitive assessment including Intelligence testing, Stroop color-word test and Trail making test, clinical interview and brain structural and functional MRI.